Cargando…
Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer
BACKGROUND: DNA damage and DNA damage repair (DDR) are important therapeutic targets for triple-negative breast cancer (TNBC), a subtype with limited chemotherapy efficiency and poor outcome. However, the role of microRNAs in the therapy is emerging. In this study, we explored whether miR-26a-5p cou...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294332/ https://www.ncbi.nlm.nih.gov/pubmed/37365643 http://dx.doi.org/10.1186/s13058-023-01663-y |
_version_ | 1785063172017750016 |
---|---|
author | Zhang, Yue Lv, Lianqiu Zheng, Renjing Xie, Rong Yu, Yuanhang Liao, Han Chen, Jianying Zhang, Bo |
author_facet | Zhang, Yue Lv, Lianqiu Zheng, Renjing Xie, Rong Yu, Yuanhang Liao, Han Chen, Jianying Zhang, Bo |
author_sort | Zhang, Yue |
collection | PubMed |
description | BACKGROUND: DNA damage and DNA damage repair (DDR) are important therapeutic targets for triple-negative breast cancer (TNBC), a subtype with limited chemotherapy efficiency and poor outcome. However, the role of microRNAs in the therapy is emerging. In this study, we explored whether miR-26a-5p could act as BRCAness and enhance chemotherapy sensitivity in TNBC. METHODS: Quantitative reverse transcription polymerase chain reaction (RT-qPCR) was used to detect the expression of miR-26a-5p in breast cancer tissues and cell lines. CCK-8 was used to measure drug sensitivity in concentration gradient and time gradient. Comet assay was used to detect DNA damage. Flow cytometry was performed to examine apoptosis. Moreover, we used western blot and immunofluorescence to detect biomarkers. Luciferase reporter assay was performed to verify the combination of miR-26a-5p and 3’UTR of target gene. Hormone deprivation and stimulation assay were used to validate the effect of hormone receptors on the expression of miR-26a-5p. Chromatin immunoprecipitation (ChIP) assays were used to verify the binding sites of ER-a or PR with the promoter of miR-26a-5p. Animal experiments were performed to the effect of miR-26a-5p on Cisplatin treatment. RESULTS: The expression of miR-26a-5p was significantly downregulated in TNBC. Overexpressing miR-26a-5p enhanced the Cisplatin-induced DNA damage and following apoptosis. Interestingly, miR-26a-5p promoted the expression of Fas without Cisplatin stimulating. It suggested that miR-26a-5p provided a hypersensitivity state of death receptor apoptosis and promoted the Cisplatin sensitivity of TNBC cells in vitro and in vivo. Besides, miR-26a-5p negatively regulated the expression of BARD1 and NABP1 and resulted in homologous recombination repair defect (HRD). Notably, overexpressing miR-26a-5p not only facilitated the Olaparib sensitivity of TNBC cells but also the combination of Cisplatin and Olaparib. Furthermore, hormone receptors functioned as transcription factors in the expression of miR-26a-5p, which explained the reasons that miR-26a-5p expressed lowest in TNBC. CONCLUSIONS: Taken together, we reveal the important role of miR-26a-5p in Cisplatin sensitivity and highlight its new mechanism in DNA damage and synthetic lethal. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13058-023-01663-y. |
format | Online Article Text |
id | pubmed-10294332 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-102943322023-06-28 Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer Zhang, Yue Lv, Lianqiu Zheng, Renjing Xie, Rong Yu, Yuanhang Liao, Han Chen, Jianying Zhang, Bo Breast Cancer Res Research BACKGROUND: DNA damage and DNA damage repair (DDR) are important therapeutic targets for triple-negative breast cancer (TNBC), a subtype with limited chemotherapy efficiency and poor outcome. However, the role of microRNAs in the therapy is emerging. In this study, we explored whether miR-26a-5p could act as BRCAness and enhance chemotherapy sensitivity in TNBC. METHODS: Quantitative reverse transcription polymerase chain reaction (RT-qPCR) was used to detect the expression of miR-26a-5p in breast cancer tissues and cell lines. CCK-8 was used to measure drug sensitivity in concentration gradient and time gradient. Comet assay was used to detect DNA damage. Flow cytometry was performed to examine apoptosis. Moreover, we used western blot and immunofluorescence to detect biomarkers. Luciferase reporter assay was performed to verify the combination of miR-26a-5p and 3’UTR of target gene. Hormone deprivation and stimulation assay were used to validate the effect of hormone receptors on the expression of miR-26a-5p. Chromatin immunoprecipitation (ChIP) assays were used to verify the binding sites of ER-a or PR with the promoter of miR-26a-5p. Animal experiments were performed to the effect of miR-26a-5p on Cisplatin treatment. RESULTS: The expression of miR-26a-5p was significantly downregulated in TNBC. Overexpressing miR-26a-5p enhanced the Cisplatin-induced DNA damage and following apoptosis. Interestingly, miR-26a-5p promoted the expression of Fas without Cisplatin stimulating. It suggested that miR-26a-5p provided a hypersensitivity state of death receptor apoptosis and promoted the Cisplatin sensitivity of TNBC cells in vitro and in vivo. Besides, miR-26a-5p negatively regulated the expression of BARD1 and NABP1 and resulted in homologous recombination repair defect (HRD). Notably, overexpressing miR-26a-5p not only facilitated the Olaparib sensitivity of TNBC cells but also the combination of Cisplatin and Olaparib. Furthermore, hormone receptors functioned as transcription factors in the expression of miR-26a-5p, which explained the reasons that miR-26a-5p expressed lowest in TNBC. CONCLUSIONS: Taken together, we reveal the important role of miR-26a-5p in Cisplatin sensitivity and highlight its new mechanism in DNA damage and synthetic lethal. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13058-023-01663-y. BioMed Central 2023-06-26 2023 /pmc/articles/PMC10294332/ /pubmed/37365643 http://dx.doi.org/10.1186/s13058-023-01663-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Zhang, Yue Lv, Lianqiu Zheng, Renjing Xie, Rong Yu, Yuanhang Liao, Han Chen, Jianying Zhang, Bo Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer |
title | Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer |
title_full | Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer |
title_fullStr | Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer |
title_full_unstemmed | Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer |
title_short | Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer |
title_sort | transcriptionally regulated mir-26a-5p may act as brcaness in triple-negative breast cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294332/ https://www.ncbi.nlm.nih.gov/pubmed/37365643 http://dx.doi.org/10.1186/s13058-023-01663-y |
work_keys_str_mv | AT zhangyue transcriptionallyregulatedmir26a5pmayactasbrcanessintriplenegativebreastcancer AT lvlianqiu transcriptionallyregulatedmir26a5pmayactasbrcanessintriplenegativebreastcancer AT zhengrenjing transcriptionallyregulatedmir26a5pmayactasbrcanessintriplenegativebreastcancer AT xierong transcriptionallyregulatedmir26a5pmayactasbrcanessintriplenegativebreastcancer AT yuyuanhang transcriptionallyregulatedmir26a5pmayactasbrcanessintriplenegativebreastcancer AT liaohan transcriptionallyregulatedmir26a5pmayactasbrcanessintriplenegativebreastcancer AT chenjianying transcriptionallyregulatedmir26a5pmayactasbrcanessintriplenegativebreastcancer AT zhangbo transcriptionallyregulatedmir26a5pmayactasbrcanessintriplenegativebreastcancer |